The abstract is read at the publisher; the summary is JClub's.
Add-on intravenous immunoglobulin (IVIG) given at 0, 4, and 8 weeks improves myositis activity at week 12 in newly diagnosed adult idiopathic inflammatory myopathies, raising Total Improvement Score to 60.0 vs 42.5 with P=.01.
- Why it matters: Evidence for IVIG in newly diagnosed idiopathic inflammatory myopathies was preliminary, and a randomized trial was needed to test whether it adds benefit to high-dose prednisone with acceptable safety.
- What they did: In a double-blind, randomized, placebo-controlled trial at a tertiary referral center, adults with newly diagnosed IIM received prednisone 1 mg/kg/d (max 80 mg/d) plus IVIG 2.0 g/kg or placebo, and outcomes were assessed through week 12.
- The result: IVIG produced higher moderate and major improvement rates (91% and 70%) than placebo (53% and 26%), with faster time to moderate response (median 4 vs 12 weeks; P=.005), and one asymptomatic deep venous thrombosis occurred in the IVIG group.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.